KOD|Kodiak Sciences Inc|Price:41.010|Chg%:-2.67

More Details of Kodiak Sciences Inc Company

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc Info



Ticker SymbolKOD

Company nameKodiak Sciences Inc

IPO dateOct 04, 2018

CEOPerlroth (Victor)

Number of employees109

Security typeOrdinary Share

Fiscal year-endOct 04

Address1250 Page Mill Rd

CityPALO ALTO

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code94304

Phone16502810850

Websitehttps://kodiak.com/

Ticker SymbolKOD

IPO dateOct 04, 2018

CEOPerlroth (Victor)

Company Executives of Kodiak Sciences Inc



Name

Name/Position

Position

Shareholding

Change

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

211.93K

+13.50%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

Dr. Bassil I. Dahiyat, Ph.D.

Independent Director

--

Dr. Taiyin Yang, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

211.93K

+13.50%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

--

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

--

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

--

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Felix J. Baker, Ph.D.

Independent Director

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

Baker Bros. Advisors LP

31.83%

Perlroth (Victor D)

4.79%

BlackRock Institutional Trust Company, N.A.

4.71%

Braidwell LP

3.31%

State Street Investment Management (US)

2.77%

Other

52.60%

Shareholders

Proportion

Baker Bros. Advisors LP

31.83%

Perlroth (Victor D)

4.79%

BlackRock Institutional Trust Company, N.A.

4.71%

Braidwell LP

3.31%

State Street Investment Management (US)

2.77%

Other

52.60%

Shareholder Types

Shareholders

Proportion

Hedge Fund

45.55%

Investment Advisor

22.85%

Investment Advisor/Hedge Fund

15.33%

Individual Investor

5.18%

Research Firm

3.11%

Private Equity

1.36%

Endowment Fund

1.11%

Pension Fund

0.23%

Bank and Trust

0.18%

Other

5.10%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

311

60.04M

96.04%

+7.96M

2025Q4

265

48.79M

79.98%

+1.64M

2025Q3

248

41.93M

79.39%

-9.11M

2025Q2

273

46.04M

87.25%

-8.67M

2025Q1

302

46.32M

87.78%

-8.84M

2024Q4

308

44.88M

85.29%

-7.98M

2024Q3

318

42.74M

81.24%

-12.36M

2024Q2

326

43.49M

82.78%

-12.58M

2024Q1

345

46.64M

88.83%

-7.18M

2023Q4

377

44.39M

84.60%

-13.12M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Baker Bros. Advisors LP

19.92M

32.66%

+2.61M

+15.07%

Dec 31, 2025

Perlroth (Victor D)

3.00M

4.91%

+300.00K

+11.13%

Mar 25, 2026

BlackRock Institutional Trust Company, N.A.

2.95M

4.83%

+546.31K

+22.77%

Dec 31, 2025

Braidwell LP

2.07M

3.4%

+2.07M

--

Dec 31, 2025

State Street Investment Management (US)

1.73M

2.84%

+899.57K

+108.06%

Dec 31, 2025

RTW Investments L.P.

1.49M

2.44%

+1.49M

--

Dec 31, 2025

TCG Crossover Management, LLC

1.45M

2.37%

+300.00K

+26.19%

Dec 31, 2025

ICONIQ Capital, LLC

1.27M

2.08%

--

Dec 31, 2025

T. Rowe Price Associates, Inc.

1.14M

1.86%

+673.93K

+145.42%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Fidelity Enhanced Small Cap ETF

0.18%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.06%

iShares Health Innovation Active ETF

0.06%

iShares Russell 2000 Value ETF

0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

0.05%

ProShares Hedge Replication ETF

0.03%

ProShares UltraPro Russell2000

0.03%

Proshares Ultra Russell 2000

0.02%

Fidelity Enhanced Small Cap ETF

Proportion0.18%

iShares Micro-Cap ETF

Proportion0.11%

Vanguard US Momentum Factor ETF

Proportion0.11%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0.06%

iShares Health Innovation Active ETF

Proportion0.06%

iShares Russell 2000 Value ETF

Proportion0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

Proportion0.05%

ProShares Hedge Replication ETF

Proportion0.03%

ProShares UltraPro Russell2000

Proportion0.03%

Proshares Ultra Russell 2000

Proportion0.02%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data